Neuromyelitis optica spectrum disorder

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

7 events
Dec 2025Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)

Tang-Du Hospital — NA

TrialRECRUITING
Jul 2024Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders

Xuanwu Hospital, Beijing

TrialRECRUITING
Jul 2024FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack

Tianjin Medical University General Hospital — PHASE2

TrialNOT YET RECRUITING
Jul 2021Biorepository and Registry for Plasma Exchange Patients

Charles M Knudson

TrialRECRUITING
Jun 2020Uplizna: FDA approved

Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

FDAcompleted
Jan 2019Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)

Beijing Tiantan Hospital

TrialRECRUITING
Jun 2012The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders

University of Texas Southwestern Medical Center

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

1

Foundation grants

Foundation Grants1

HealthWell Foundation — Neuromyelitis optica spectrum disorder

HealthWell Foundation

OpenContact for detailsApply ↗

Patient Assistance Programs1

SOLIRIS

Alexion Pharmaceuticals Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

3 FDA-approved

Uplizna

(INEBILIZUMAB)Orphan drug

Horizon Therapeutics USA, Inc.

CD19-directed Cytolytic Antibody [EPC]

12.1 Mechanism of Action The mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD, IgG4-RD, and gMG is presumed to involve bin...

Approved Jun 2020FDA label ↗

Enspryng

(SATRALIZUMAB)Orphan drugstandard

Genentech, Inc.

12.1 Mechanism of Action The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD is unknown but is presumed to involve in...

FDA label ↗

Ultomiris

(RAVULIZUMAB)Orphan drugstandard

Alexion Pharmaceuticals Inc.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

5 active trials
1N/A
4Unknown
5Total recruiting
Search clinical trials for Neuromyelitis optica spectrum disorder

Recent News & Research

No recent news articles indexed yet for Neuromyelitis optica spectrum disorder.
Search PubMed for Neuromyelitis optica spectrum disorder

Browse all Neuromyelitis optica spectrum disorder news →

Specialist Network

Top 6 by expertise

View all Neuromyelitis optica spectrum disorder specialists →

Quick Actions